Allantoin

Small moleculeexperimental

The aluminum salt of Allantoin, Alcloxa combines the astringent and anti-microbial properties of aluminum with the anti-irritant, soothing and healing properties of Allantoin. Alcloxa is particularly suited for use in anti-perspirants, acne treatments and foot care products. Alcloxa is a compound that combine the properties of aluminum salts with the properties of allantion. The allantion component ehhances the action of the aluminum salts and serves to overcome irritations experienced by many individuals who may be sensitive to the use of aluminum alts. The aluminum component reduces sweat by causing the sweat gland ducts swell. Alcloxa also add to the antiperspirant properties the deodorant effect because of its bacteriostatic action. It showed bacteriostatic properties at concentrations of 0.2% particularly against Gram + bectaria (B. subtilis, S. aureus, P. vulgaris, Pityrosporum ovale). This is ascribable to two different mechanisms: first bacterial growth is retarded due to a decrease in the amount of water present, second aluminum salt have itself an antimicrobial action. In baby products is indicated for its healing reparative action, in the treatment of diaper rash. Also is approved in haemorrhoidal product for its soothing and keratolytic action. In oral care products Alcloxa is useful for its astringent antibacterial properties. It is very indicated in formulations for sensitive teeth, periodontal and gum diseases (like gingivitis, irritable and bleeding gums). Use levels: 0.1-1%. − In antiacne products the slightly astringent effect promotes healing of pustules and acne lesions. It reduces the extension of infected skin eruptions, healing them and developing a soothing action. May be used alone or also in combinations with other antimicrobial agents in order to fight acne more effectively. Use levels: 0.5-2.0%. — NCATS

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2008 (NCT00713674)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetSupplementation

    supplementation

Chemistry & pharmacology

Loading structure…

SMILES

NC(=O)NC1NC(=O)NC1=O
Mol. weight
158.1154 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5-ureidohydantoin
  • 5-ureidohydantoin
  • 5-ureidohydantoin
  • allantion
  • allantoin
  • allantoin
  • allantoin
  • allantoin
  • allantoin
  • allantoin
  • allantoin
  • allantoin
  • allantol
  • alwextin
  • glyoxyldiureid
  • glyoxyldiureide
  • glyoxyldiureide
  • glyoxyldiureide
  • glyoxylic diureide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02708628N/ADec 1, 2015Suleymaniye Birth And Women's Health Education And Research Hospital
NCT01863407Phase 3Apr 1, 2013Beijing Bozhiyin T&S Co., Ltd.
NCT00825565Phase 2Feb 1, 2009Northwestern University
NCT00713674N/AMar 1, 2008Mercy Research, Mercy/St. John's Hospital - Springfield
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Beijing Bozhiyin T&S Co., Ltd.For profit1112013
Mercy ResearchAcademic/Hospital1112008
Mercy/St. John's Hospital - SpringfieldAcademic/Hospital1012008
Northwestern UniversityAcademic/Hospital1112009
Suleymaniye Birth And Women's Health Education And Research HospitalAcademic/Hospital1112015
5 organizations
Page 1 / 1